[{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL-2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Cairo Laboratory","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NKTR-255","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nektar Therapeutics \/ Cairo Laboratory","highestDevelopmentStatusID":"4","companyTruncated":"Nektar Therapeutics \/ Cairo Laboratory"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Cellular Biomedicine Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Collaboration","leadProduct":"C-TIL051","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nektar Therapeutics \/ Cellular Biomedicine Group","highestDevelopmentStatusID":"7","companyTruncated":"Nektar Therapeutics \/ Cellular Biomedicine Group"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Axitinib","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nektar Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Nektar Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Bempegaldesleukin","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nektar Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Nektar Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Bempegaldesleukin","moa":"IL-2-beta-receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL-2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Agreement","leadProduct":"Rezpegaldesleukin","moa":"IL-2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL-2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"Rezpegaldesleukin","moa":"IL-2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ TCGX","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ TCGX"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL-2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Agreement","leadProduct":"Antihemophilic Factor Recombinant, PEGylated","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nektar Therapeutics \/ HealthCare Royalty","highestDevelopmentStatusID":"15","companyTruncated":"Nektar Therapeutics \/ HealthCare Royalty"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NKTR-255","moa":"IL-15 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Bempegaldesleukin","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Bempegaldesleukin","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Bempegaldesleukin","moa":"IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Loxicodegol","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Nykode Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Bempegaldesleukin","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nektar Therapeutics \/ Nykode Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Nektar Therapeutics \/ Nykode Therapeutics"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"SFJ Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Bempegaldesleukin","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nektar Therapeutics \/ SFJ Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Nektar Therapeutics \/ SFJ Pharmaceuticals"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"TrialNet","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Protein","year":"2025","type":"Collaboration","leadProduct":"Rezpegaldesleukin","moa":"IL-2 receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ TrialNet","highestDevelopmentStatusID":"6","companyTruncated":"Nektar Therapeutics \/ TrialNet"}]
Find Clinical Drug Pipeline Developments & Deals by Nektar Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
